Clinical Research Directory
Browse clinical research sites, groups, and studies.
Novel Imaging Markers in SPMS
Sponsor: University of Utah
Summary
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.
Official title: Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis
Key Details
Gender
All
Age Range
35 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
11
Start Date
2022-06-01
Completion Date
2023-09-01
Last Updated
2026-08-13
Healthy Volunteers
No
Conditions
Interventions
Ferumoxytol infusion
Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
Gadoteridol
Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
MRI Brain and Cervical Spine
3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
Locations (1)
University of Utah Health Imaging and Neurosciences Center
Salt Lake City, Utah, United States